TrialEndocrine journal2017

Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial.

Ryotaro Bouchi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.